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Abstract
Idiopathic achalasia is a primary esophageal motor disorder characterized by esophageal aperistalsis
and abnormal lower esophageal sphincter (LES) relaxation in response to deglutition. It is a rare
disease with an annual incidence of approximately 1/100,000 and a prevalence rate of 1/10,000. The
disease can occur at any age, with a similar rate in men and women, but is usually diagnosed
between 25 and 60 years. It is characterized predominantly by dysphagia to solids and liquids, bland
regurgitation, and chest pain. Weight loss (usually between 5 to 10 kg) is present in most but not
in all patients. Heartburn occurs in 27%–42% of achalasia patients. Etiology is unknown. Some
familial cases have been reported, but the rarity of familial occurrence does not support the
hypothesis that genetic inheritance is a significant etiologic factor. Association of achalasia with viral
infections and auto-antibodies against myenteric plexus has been reported, but the causal
relationship remains unclear. The diagnosis is based on history of the disease, radiography (barium
esophagogram), and esophageal motility testing (esophageal manometry). Endoscopic examination
is important to rule out malignancy as the cause of achalasia. Treatment is strictly palliative. Current
medical and surgical therapeutic options (pneumatic dilation, surgical myotomy, and pharmacologic
agents) aimed at reducing the LES pressure and facilitating esophageal emptying by gravity and
hydrostatic pressure of retained food and liquids. Although it cannot be permanently cured,
excellent palliation is available in over 90% of patients.
Background
Definition and epidemiology
Idiopathic (primary) achalasia is a primary esophageal
motor disorder of unknown etiology characterized by
esophageal aperistalsis and abnormal lower esophageal
sphincter (LES) relaxation in response to deglutition [1-
4]. It is a rare disease with an annual incidence of approx-
imately 1/100,000 and a prevalence rate of 10/100,000
[5], but it is frequent enough to be encountered at least
once by every gastroenterologist.
History
Achalasia was first described and termed by Sir Thomas
Willis in 1674, where he suggested that the disease is due
to the loss of normal inhibition in the distal esophagus
[6]. Since then, the development of new diagnostic tech-
niques stimulated new ideas on the etiology and patho-
physiology of the disease leading to various theories in
identifying the nature of motor disturbances in esopha-
geal regions. However, the initiating cause is still elusive
[3,6,7].
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Studies have shown a similar rate for achalasia in men and
women. The disease is characterized predominantly by
dysphagia to solids and liquids, bland regurgitation, and
chest pain. The diagnosis of achalasia is relatively easy to
make with a good history, radiography (barium esoph-
agogram), and esophageal motility testing (esophageal
manometry). Endoscopic examination is important to
rule out malignancy as the cause of achalasia [8].
Since neuronal degeneration is irreversible, treatment of
achalasia is strictly palliative. Current medical and surgi-
cal therapeutic options proposed for this well-recognized
motor disorder of esophagus are aimed at reducing the
LES pressure and facilitating esophageal emptying by
gravity and hydrostatic pressure of retained food and liq-
uids [8-12]. These therapeutic options include pneumatic
dilation, surgical myotomy, and less effectively pharma-
cologic agents [11,13].
In this review article we detail on the pathogenesis, etiol-
ogy, diagnosis, and treatment options for this motor dis-
order of esophagus.
Clinical features
Achalasia is one of the most investigated motor disorders
of the esophagus [4,7]. The disease can occur at any age
but it is usually diagnosed between 25 and 60 years. Pro-
gressive dysphagia to solids followed by liquids (82%–
100%) is the first clinical symptom of achalasia [13].
Although dysphagia can occur in patients with other
esophageal motility disorders, this symptom is most char-
acteristic of achalasia and strongly suggests the diagnosis.
Regurgitation not responding to proton pump inhibitor
(PPI) therapy and weight loss can be seen in between 30%
to 90% of the patients. Regurgitation of material retained
in the dilated esophagus, especially during supine posi-
tion at night, may lead to aspiration. Weight loss (usually
between 5 to 10 kg) is not present in all patients.
Chest pain is another presenting symptom of achalasia
(17%–95%). The occurrence of this symptom is unrelated
to the LES pressure [4,13]. Chest pain seems to be the only
symptom that is affected by the age and gender [4,14-16],
as chest pain has been reported to be 1.7 more frequent in
women than in men with achalasia [15].
Heartburn, the main symptom of gastroesophageal reflux
disease (GERD), may also occur infrequently (27%–42%)
in achalasia patients. Although the mean LES pressure in
patients with achalasia who experience heartburn has
been reported to be significantly lower than that in
patients without the symptom [17], this symptom is most
likely related to the production of lactic acid from retained
foods or exogenous ingested acidic materials such as car-
bonated drinks [1].
Difficulty belching has also been reported in up to 85% of
the patients, and is due to a defect in relaxation of the
upper esophageal sphincter in these patients.
The information on cancer risk in achalasia is insufficient.
There are many studies on this and the great majority of
them suggests a significantly increased risk [18]; however,
there are currently no recommendations for surveillance
of achalasia patients for esophageal cancer.
Pathophysiology of idiopathic achalasia
Distal esophageal wall and LES are innervated by postgan-
glionic neurons, consisting of excitatory and inhibitory
neurons. The excitatory neurons release acetylcholine
while the inhibitory neurons release nitric oxide (NO)
and vasoactive intestinal polypeptide (VIP), resulting in
esophageal and LES contractions and relaxations, respec-
tively [3].
The NO and VIP releasing inhibitory neurons are the tar-
get in idiopathic achalasia. Loss of these inhibitory neu-
rons due to either intrinsic or extrinsic causes will result in
the manometric consequence of failure of LES relaxation
as well as loss of esophageal peristalsis [3,4,19].
Several studies on humans and animals [20,21] have sug-
gested that extrinsic causes such as lesions located in the
central nervous system (CNS) may produce manometric
findings of achalasia. Abnormalities of the vagal nerve fib-
ers outside the CNS has also been associated with achala-
sia; however, extrinsic innervation abnormalities are rare
findings in achalasia patients [22-24] and are thus proba-
bly not the primary mechanism of the disease.
In contrast, intrinsic loss of inhibitory myenteric neurons
in both the esophagus and LES in patients with achalasia
has been reported as the most likely contributory factor in
the pathophysiology of achalasia. Studies [25-27] have
suggested that loss of VIP and NO secreting neurons leads
to an imbalance between the excitatory and inhibitory
neurons of the myenteric plexus, producing irreversible
manometric changes in such patients. Morphologic stud-
ies of the esophageal myenteric plexus have also con-
firmed the loss of myenteric ganglion cells in achalasia
[28,29]. In such studies, loss of ganglion cells was associ-
ated with inflammation and, even in severe cases, the
myenteric nerves had been replaced by collagen.
Etiology of idiopathic achalasia
Familial
The existence of familial cases suggest that achalasia is an
inherited disease [30-33]. Such familial cases have beenOrphanet Journal of Rare Diseases 2007, 2:38 http://www.OJRD.com/content/2/1/38
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mostly seen in the pediatric population, between siblings
and in a few cases in monozygotic twins [30,31]. There are
also a few reports of a parent-child association for achala-
sia [32]. Although these evidences suggest an autosomal
recessive mode of inheritance for this disease [30,33], the
rarity of familial occurrence does not support the hypoth-
esis that genetic inheritance is a significant etiologic fac-
tor. Instead, it is proposed that genetic predisposition in
such individuals probably increases their susceptibility to
acquiring achalasia after exposure to common environ-
mental factors that may play a role in the pathogenesis
[3].
Infection
Several studies have suggested a possible association
between viral infections and achalasia [34,35]. In such
studies, various viral antibodies were measured in sera of
the patients with achalasia and the normal controls, and
only measles and varicella zoster virus antibodies were
found to be higher among a number of achalasia patients.
On the other hand, in the clinical setting not all patients
with measles and varicella will develop achalasia [3].
Using polymerase chain reaction, other studies [36,37]
have demonstrated no evidence of any viral products in
the esophageal tissue of patients with achalasia. In addi-
tion, even those studies that found evidence of a virus,
could not establish a causal relationship [3], thus, the
infectious etiology of achalasia remains an unclear matter.
Autoimmune
Increased prevalence of circulating antibodies against
myenteric plexus in some achalasia patients led to the sug-
gestion of a role for auto-antibodies in the pathogenesis of
this disease [38,39]; however, a recent study by Moses et al
[40] suggested that these circulatory antibodies are most
likely the result of a nonspecific reaction to the disease
process instead of being the cause of the disease. This idea
was supported by detection of similar antibodies in
patients without achalasia.
Ultra-structural studies [41,42] of the esophageal tissue of
patients with achalasia have also found inflammatory
infiltrates around myenteric neurons, while in control
group normal myenteric plexus was found without infil-
tration.
Multiple case-control studies [43-46] have reported a sig-
nificant association with HLA class II antigens in idio-
pathic achalasia. The most recent study [46] also showed
that achalasia patients with associated HLA allele were
found to have higher prevalence of circulating antimy-
enteric autoantibodies, which supported the autoimmune
etiology [3]. HLA association also suggests immunoge-
netic predisposition for idiopathic achalasia; however,
this should be taken with caution as not all the achalasia
patients have associated HLA antigens.
Diagnosis and differential diagnosis
The diagnosis of idiopathic achalasia is relatively straight
forward with a well-documented medical history, radiog-
raphy, and esophageal motility testing.
History
In the early stages of the disease, dysphagia may be very
subtle and can be misinterpreted as dyspepsia, poor gas-
tric emptying, or stress. The presence of heartburn due to
food stasis can add to this confusion. As the disease
progresses, difficulty swallowing characteristically occurs
with both solid foods, and liquids. The dysphagia is more
to solids than liquids. To ease progression of the food
bolus, patients usually modify their eating habits: eating
more slowly or use certain maneuvers such as raising the
arms, or arching the back.
Esophageal manometry
Manometry is the gold standard means for establishing
the diagnosis of achalasia. Aperistalsis is always present in
the esophageal body. Wet and dry swallows are followed
by simultaneous contractions [1]. The amplitude of the
contractions is low (10–40 mm Hg) and repetitive in most
of the cases [6] (Figure 1).
The LES displays high pressure at rest and fails to relax, or
relaxes only partially with swallowing (Figure 1). Up to
40% of the patients with achalasia have normal LES pres-
sure (10–40 mm Hg); however, low pressure LES is not
seen in untreated achalasia patients [47].
Vigorous achalasia was described in 1957 as a subset of
achalasia with a higher contraction amplitude (>37 mm
Hg), minimal esophageal dilatation, prominent tertiary
contractions, and higher incidence of chest pain. A recent
study comparing patients with classic and vigorous acha-
lasia showed that the original manometric and radio-
graphic description of vigorous achalasia is accurate;
however, the incidence of the chest pain seems to be sim-
ilar between the two groups [48].
Timed barium esophagogram
Barium swallow was initially used by Vantrappen et al
[49] in achalasia patients to determine the cause of per-
sistent symptoms after treatment with pneumatic dila-
tion. This led to suggestion that barium esophagogram
with fluoroscopy is the single best diagnostic study for
achalasia. The characteristics of achalasia in barium
esophagogram are the loss of primary peristalsis in the
distal two third of the esophagus, poor emptying with
retained food and saliva producing an air-fluid level at the
top of the barium column. In the chronic stages of the dis-Orphanet Journal of Rare Diseases 2007, 2:38 http://www.OJRD.com/content/2/1/38
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ease, there is dilated esophagus or sigmoid tortuosity and,
sometimes in advanced cases, massive dilatation of
esophageal body [1]. The typical finding in achalasia is the
presence of smooth tapering of the lower esophagus lead-
ing to a closed LES, resembling a bird's beak (Figure 2).
In 1997 de Oliveira et al [50] described timed barium
esophagogram as a simple, noninvasive, and widely avail-
able barium technique for evaluating esophageal empty-
ing in patients with achalasia. The films in this technique
are taken at 1, 2 and 5 minutes after the last swallow of
barium; the purpose of 2 min film is to assess interim
emptying. The technique is simple to interpret because
both radiologists and gastroenterologists can accurately
assess emptying. Emptying can be assessed by the height
time width of the barium column or a qualitative estimate
of emptying. This method can be also used in predicting
the success of treatment in patients with achalasia, which
will be discussed later [12,50].
Endoscopy
All patients with suspected achalasia should undergo
upper gastrointestinal endoscopy to exclude pseudoacha-
lasia. Pseudoachalasia results from a tumor at the esoph-
agogastric junction, therefore, this area needs to be
examined carefully during the procedure [1,3]. At endos-
copy, the esophageal body may look normal, or dilated,
atonic and often tortuous. The mucosa looks normal, but
sometimes it is thickened or friable with even superficial
ulcers secondary to chronic stasis or candida esophagitis.
The LES is closed even with insufflations of air, but the
Barium swallow Figure 2
Barium swallow. Dilated esophagus with retained column of 
barium and "bird's beaking" suggestive of achalasia.
Manometry Figure 1
Manometry. Isobaric simultaneous esophageal body contrac-
tions with incomplete LES relations classic for the diagnosis 
of achalasia.Orphanet Journal of Rare Diseases 2007, 2:38 http://www.OJRD.com/content/2/1/38
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endoscope can easily pass this area with gentle pressure. If
a tumor is suspected because of rapid progression of
symptoms, or the need of excess pressure to open the LES,
repeated endoscopy examinations with biopsies and
endoscopic ultrasound and CT chest are mandatory.
Management
Despite several insights into the pathophysiologyof acha-
lasia, the etiology of the disorder still remains unknown;
thus, it is not surprising that the treatment is entirely pal-
liative. If untreated, the disease course leads to a progres-
sive stasis and dilation of the esophagus occurs increasing
the subsequent risk of aspiration, weight loss, and malnu-
trition.
The objective of the current therapeutic options for acha-
lasia is to reduce the LES tone, relieve functional obstruc-
tion to the esophageal transit, and facilitate esophageal
emptying by gravity. This goal can be achieved by either
non-surgical methods such as traditional muscle relax-
ants, chemical denervation (i.e.  botulinum toxin), and
pneumatic dilation, or surgical myotomy. These methods
vary in their level of invasiveness and risk of adverse
effects [10,51].
Pharmacologic treatment
Pharmacologic agents used for achalasia are mostly
smooth muscle relaxants that act by reducing LES pres-
sure. Calcium channel blockers and long-acting nitrates
are the two most common medications used [52,53].
Other less commonly used agents include anti-choliner-
gics (atropine, dicyclomine, cimetropium, bromide),
beta-adrenergic agonists (terbutaline), and theophylline
[13].
Nifedipine is one of the well-studied calcium channel
blockers for the treatment of achalasia. It is available in a
sublingual formulation, resulting in rapid absorption and
clinical response. Studies show that the time to maximum
effect for sublingual nifedipine is 20 to 45 minutes; there-
fore, it is recommended nifedipine (10–30 mg) to be
given sublingually 30 to 45 minutes before meals and at
bedtime [13]. The efficacy of nifedipine largely varies (0%
to 75% in clinical trials), with side effects reported by up
to 30% of the patients [10,13].
Sublingual isosorbide dinitrate is also effective in decreas-
ing LES pressure in achalasia patients, resulting in symp-
tom improvement in 53% to 87% of patients. The effect
of nitrate is more rapid than that of nifidipine, but has a
shorter duration; thus, sublingual Isordil® (5 mg) is com-
monly administered only 10 to 15 minutes before meals
[13].
In a study comparing the effect of sublingual nifedipine to
sublingual isosorbide dinitrate, both drugs decreased LES
pressure, but the effect of nitrate was slightly better than
that of nifidipine (65% vs. 49% respectively) [53].
Pharmacologic agents rarely yield satisfactory long-term
alleviation of symptoms and are now only used in
patients who are not candidates for pneumatic dilation or
surgery. They also can be used during the planning stage
for more effective therapy.
Botulinum toxin treatment
Botulinum toxin (BT) was first used in achalasia patients
by Pasricha and his colleagues [2,54,55]. The rational was
that the injection of BT in the LES reduces the LES pressure
and improves the "passive" esophageal emptying by
counterbalancing the selective loss of inhibitory neurons
in the myenteric plexus [2,10]. BoTx A 80–100 Units of
are injected through a 5-mm sclerotherapy needle into the
LES. Aliquots equaling 20 to 25 U of the toxin are injected
into each quadrant of the LES.
Following single injection of BT, relief of symptoms has
been reported in almost 80% of patients. After six
months, 50% of the patients may remain in remission
[1,2,55,56], while others will need repeated injections, or
other treatment options such as pneumatic dilation (PD)
or myotomy [1,55,56]. Table 1 reflects the symptom
response rate as well as percent of LES pressure drop after
treatment with BT over a period of 12 months in most val-
uable studies.
Only a few studies are available on the long-term efficacy
of BT. Our initial randomized trial found a one year suc-
cess rate of 32% in achalasia patients treated with BT [2].
Annese et al [57] reported a success rate of 68% at 24
months after receiving repeated BT injection, while Pas-
richa et al [58] found a 30% efficacy rate after a mean fol-
low-up of 2 years.
Injection of BT seems to be simple and safe, without car-
rying any risk of perforation. Mild chest pain has been
reported in a few cases shortly after the injection, but it
does not usually require specific intervention. However,
surgeons have also reported that myotomy is more diffi-
cult in patients with repeated BT injection due to
increased adhesion of the muscular layer [51].
Post-treatment evaluations have revealed that neither pre-
treatment LES pressure, amplitude of esophageal contrac-
tions, nor duration of illness could be used to predict the
outcome of BT injection. Instead, young age and male
gender were found to adversely affect the outcome
[58,59]. Symptom relief was found to last up to 1 to 2
years with a single injection in the elderly [8,9]. Of the dif-Orphanet Journal of Rare Diseases 2007, 2:38 http://www.OJRD.com/content/2/1/38
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ferent BT regimen, two injections of 100 U of BT 1 month
apart appears to be the most effective therapeutic schedule
[57]. Seventy six percent of those responded to the first
injection will respond to the second injection; however,
the response to further injection usually decreases due to
anti body formation against the BT protein.
Overall, BT is recommended to be most effective in elderly
patients, in whom dilation or surgery represent a high
risk, or in patients with co-morbid illnesses who are not
candidates for PD or myotomy.
Pneumatic dilation
Pneumatic dilation (PD) is the most effective non-surgical
treatment option for patients with achalasia [6]. It uses the
air to dilate the esophageal lumen and disrupt the circular
muscle fibers of the LES [1]. The most commonly used
balloons are nonradiopaque polyethylene Microvasive
Rigiflex dilators that can be passed over a guide wire and
the Witzel dilator, which is passed in a retrograde fashion
over the endoscope.
The Rigiflex baloons come in three different diameters
(3.0, 3.5, and 4.0 cm). No only the procedure requires
sedation, but also all the PD candidates should be surgical
candidates as up to 5% of patients may need surgical
intervention due to perforation. The PD 3 cm is usually
used first. Good to excellent relief of symptoms are
reported in 50% to 93% of patients [13]. In case of symp-
tom relapse, graded PD (increasing the size of the balloon
diameter) seems to improve the clinical response.
Cumulatively, dilation with 3.0-, 3.5-, and 4.0-cm balloon
diameters results in good to excellent symptomatic relief
in 74%, 86%, and 90% of treated patients, respectively
with an average follow-up of 1.6 years [13]. Of the few
prospective studies on the long-term efficacy of PD, Eck-
ardt et al followed 54 consecutive patients treated with PD
every 2 years [59] and reported when follow-up on the
patients was extended further (for a median of 13.8 years),
an overall 5 year remission of 40% and a 10-year remis-
sion rate of 36% was observed. They found that repeated
dilations only mildly improved the clinical response [60].
Other studies have shown good to excellent symptom
improvement in 50–89% of patients over a mean follow-
up of 4 years [13,61,62].
Although PD is an outpatient procedure that is performed
under standard endoscopic sedation, there is still a small
but significant risk of perforation. The cumulative perfora-
tion rate with Rigiflex balloons is reported to be 2% [13].
Current knowledge has let us to make some predictions
on the outcome of pneumatic dilation. The failure rate of
PD is suggested to be higher in children and adolescents
than in elderly patients. Our recent study also showed a
predictor role for age and gender, as young male patients
do not do as well with the 3.0 cm Rigiflex balloon dilation
[63]. Vela et al [64], later confirmed these observations.
There is also evidence that a post-treatment LES pressure
of less than or equal to 15 mmHg correlates with success-
ful treatment outcome [61]. The role of radionuclide stud-
ies in predicting the outcome of PD is in doubt.
Esophageal emptying in radionuclide studies of two
patients post-therapy showed a correlation with symptom
improvement [65]; however, larger studies failed to estab-
lish a definite role for this method in predicting the suc-
cess of the treatment [59,66,67].
Our recent studies [12,61,68,69] suggest timed barium
esophagogram as a better predictor of treatment success
after PD. We have found that in almost 70% of the
patients, the height of the barium column at 5 minute
post-therapy correlates with symptom improvement
(concordant group), while in others esophageal emptying
was poor despite reports of excellent symptom relief (dis-
cordant group). Nearly all patients in discordant group
failed the treatment within 1 year after treatment, while
Table 1: Effect of botulinum toxin on achalasia
Study Method Number of 
patients enrolled
% LES pressure 
decreased post 
treatment
Remission rate at 
1 months
Remission rate at 
6 months
Remission rate at 
12 months
Pasricha et al, [55] Randomized 
control trial
21 33% 90% 44% ___
Fishman et al, [56] Prospective study 60 ___ 70% ___ 36%
Gordon et al, [75] Prospective study 16 ___ 75% 48% ___
Vaezi et al, [2] Randomized trial 24 1% 60% 50% 32%
Annese et al, [71] Randomized trial 16 49% 100% ___ 12.5%
Pasricha et al, [58] Prospective study 31 45% 90% 64% ___
Martinek et al, [76] Prospective 
cohort study
49 65% 93% ___ 41%
Zaninotto et al, 
[77]
Randomized 
controlled trial
40 ___ ___ 66% 34%Orphanet Journal of Rare Diseases 2007, 2:38 http://www.OJRD.com/content/2/1/38
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77% of the concordant group were still in symptom
remission after 6 years of follow-up [12]. Therefore, it is
suggested that the timed barium esophagogram not only
assesses treatment shortly after therapy, it can also predict
the poor response to the treatment if the patient has
retained barium post pneumatic dilation.
Surgical cardiomyotomy
Surgical management of achalasia involves performing a
Heller myotomy (HM), combined with an antireflux pro-
cedure (Toupet or Dor). For many years this operation has
been performed through a laparotomy, often with the
addition of a fundoplication, or through a left thoracot-
omy [70]. However, the advent of minimally invasive sur-
gery (laparoscopic myotomy) has resulted in several
advantages such as superior visualization of the gastro-
esophageal junction, the ability of adding an antireflux
procedure, a shorter hospital stay (2 days compared with
5–7 days), reduced morbidity, and quicker return to daily
activity [13,70].
A cumulative good to excellent clinical response rate of
94% has been reported for laparoscopic cardiomyotomy
over a short period of time. Studies on long-term outcome
of myotomy are summarized in Table 2. The major disad-
vantages of myotomy are incomplete myotomy and the
possibility of significant GERD. Table 2 also shows the
rate of developing GERD after myotomy in the most valu-
able studies reported.
The preferred treatment after a failed myotomy is PD. A
recent study on untreated achalasia patients and patients
with failed myotomy reports no increased risk of perfora-
tion with performing PD after Heller myotomy. However,
this study also indicates that despite lower LES pressure,
patients undergoing PD after failed myotomy do not do as
well as untreated cases [11].
Finally, laparoscopic surgery on achalasia patients that
used to be only done on those that relapsed after graded
pneumatic dilation is increasingly being performed on
healthy achalasia patients younger than 40 years. In addi-
tion, surgery may be indicated as the first line therapy for
patients with tortuous esophagus, esophageal diverticula,
or previous surgery on the gastroesophageal junction.
Comparison of the procedures
Several randomized trials suggest that pneumatic dilation
is more effective than botulinum toxin [2,71,72]. Our
study, which was one of the largest studies comparing the
outcome of two therapies, suggested that both therapies
are effective at 1 month, but PD results in significantly
better symptom improvement at 12 months compared
with BT (70% vs. 32% respectively) [2]. These findings
indicate that botulinum toxin is inferior to pneumatic
dilation for sustain symptom relief. A study on cost-effec-
tiveness of treatments also suggest that in long-term PD is
a less cost-effective treatment for achalasia compared to
BT [73].
Comparison of PD and HM also shows that there is no
difference in the early outcome of these treatments, and
the success rate of both methods decreases over time
(90% vs. 89% respectively at 6 months, to 44% vs. 56% at
6 years) [64]. Studies also suggest that laparoscopic myo-
tomy is not a cost-effective therapy as the initial cost is too
high [73]. However, it is an effective treatment modality
in patients with achalasia who have failed to respond to
PD, as the 10-year remission rate in these patients follow-
ing myotomy is shown to be 77% comparing to 72% and
45% in patients "successfully" treated with a single PD
and patients undergoing several dilations respectively
[74].
Table 2: Long-term result of laparoscopic myotomy with fundoplications
Study Method Method of surgery Number of 
patients enrolled
Length of follow-
up
Good to excellent 
response
GERD* 
complication
Bessell et al, [78] Prospective Laparoscopic 
HM**
167 5 years 77% Not mentioned
Vella et al, [64] Retrospectivecoho
rt
88% Laparoscopic 
and 12% open HM
73 6 years 57% 36%
Dang et al, [79] Retrospective 81% Laparoscopic 
and 9% open HM
22 3 years 76% Not mentioned
Raiser et al, [80] Retrospective Laparoscopic or 
thoracoscopic HM
35 1–4 years 97% Not mentioned
Hunt et al, [81] Retrospective Laparoscopic HM 70 2.9 years 81% 4.5%
Frantzides et al, 
[82]
Retrospective Laparoscopic HM 53 3 years 92% 9%
Zaninotto et al, 
[83]
Prospective Laparoscopic HM 100 2 y 92% 7%
*GERD Gastroesophageal reflux disease; **HM Heller myotomyOrphanet Journal of Rare Diseases 2007, 2:38 http://www.OJRD.com/content/2/1/38
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Therefore, to make a decision on the treatment of achala-
sia, patients should be involved in an honest discussion
on the efficacy, possible complications, as well as cost-
effectiveness of each of the therapeutic options, and
patients' informed decision should guide therapy.
Conclusion
Achalasia is a motor disorder of the esophagus character-
ized by dysphagia, regurgitation, and chest pain. Although
it cannot be permanently cured, excellent palliation is
available in over 90% of patients. As a result of the
advances in pneumatic dilation and laparoscopic Heller
myotomy, most patients with achalasia can now choose
between these two treatments. The injection of botulinum
toxin endoscopically into the LES is usually reserved for
elderly, or patients who are not candidates for pneumatic
dilation or surgery. In patients unresponsive to graded
pneumatic dilation, esophageal myotomy via the laparo-
scopic method should be performed. In myotomy fail-
ures, repeat pneumatic dilation should be attempted.
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